UT-MD Anderson Cancer Center: Novel Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia
September 18, 2024
September 18, 2024
HOUSTON, Texas, Sept. 18 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Sept. 17, 2024:
* * *
Eighty percent of patients achieved complete remission when treated with decitabine, venetoclax and ponatinib in Phase II trial
* * *
According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic . . .
* * *
Eighty percent of patients achieved complete remission when treated with decitabine, venetoclax and ponatinib in Phase II trial
* * *
According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic . . .